Wells Fargo raised the firm’s price target on Medtronic (MDT) to $100 from $98 and keeps an Overweight rating on the shares. Medtronic’s Q1 EPS beat consensus estimates driven by higher revenue, the analyst tells investors in a research note. Wells believes Elliott’s involvement is positive given their recent healthcare track record.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Positive Outlook for Medtronic Amid Strategic Changes and Elliott Management Investment
- Medtronic Reports Strong Q1 FY26 Results
- Medtronic Stock (MDT) Slides Despite Corporate Re-Jig to Boost Ailing Valuation
- Medtronic’s Mixed Performance and Strategic Uncertainty Lead to Hold Rating
- Medtronic price target raised to $90 from $87 at Stifel